Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 209 publications

Optimizing the right time to start sickle cell therapies.

Optimizing the right time to start sickle cell therapies.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.

Journal: Journal of comparative effectiveness research
Published: November 24, 2025

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Journal: Molecular pharmaceutics
Published: September 07, 2025

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice.

Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: August 15, 2025

Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective.

Equine Metabolism of Voxelotor and Its Impact on Hematological Indices: A Doping Control Perspective.

Journal: Drug testing and analysis
Published: June 12, 2025

Voxelotor (Oxbryta) Binds Multiple Hemoglobin Sites and Influences Protein Structure.

Voxelotor (Oxbryta) Binds Multiple Hemoglobin Sites and Influences Protein Structure.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025

Reversible Diffusion-Restricting White Matter Lesions in Sickle Cell Disease During Pain Crises: A Case Report.

Reversible Diffusion-Restricting White Matter Lesions in Sickle Cell Disease During Pain Crises: A Case Report.

Journal: The Neurohospitalist
Published: May 08, 2025

Effect of dalcetrapib, voxelotor and their combination on red blood cell deformability and sickling in sickle cell disease.

Effect of dalcetrapib, voxelotor and their combination on red blood cell deformability and sickling in sickle cell disease.

Journal: Clinical hemorheology and microcirculation
Published: April 21, 2025

Osivelotor for the treatment of sickle cell disease.

Osivelotor for the treatment of sickle cell disease.

Journal: Expert opinion on pharmacotherapy
Published: April 03, 2025

Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization Inhibitor.

Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization Inhibitor.

Journal: ACS medicinal chemistry letters
Published: February 11, 2025

Rapid withdrawal of voxelotor can precipitate sickle cell disease related crisis.

Rapid withdrawal of voxelotor can precipitate sickle cell disease related crisis.

Journal: Annals of hematology
Published: January 27, 2025
Showing 1-12 of 209

Last Updated: 01/07/2026